Continuous Renal Replacement Therapy Market By Product (Dialysates and Replacement Fluids, Disposables, CRRT Systems), By Modality (Continuous Venovenous Hemofiltration (CVVH), Continuous Venovenous Hemodiafiltration (CVVHDF), Continuous Venovenous Haemodialysis (CVVHD), Slow Continuous Ultrafiltration (SCUF)), By Age Group (Adults, Pediatrics): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global continuous renal replacement therapy market was valued at $1,249.21 million in 2021, and is projected to reach $2,622.44 million by 2031, registering a CAGR of 7.7% from 2022 to 2031.
Continuous renal replacement therapy (CRRT) is a slow and smooth continuous extracorporeal blood purification process. It is usually implemented over 24 hours to several days with gentle removal of fluid and excess uremic toxins. This technique is usually based on the physiological principles of diffusion, ultrafiltration, convection, and adsorption.
The key factors which drive the growth of market are rise in the incidence of Acute Kidney Injury (AKI), increase in incidence of sepsis and rise in adoption various key strategies by key players operating in market.
In addition, rise in the demand for continuous renal replacement therapy worldwide is the major factor that boosts the growth of the market. For instance, in February 2021, the Journal Kidney360 has stated that demand for renal replacement therapy increased during the COVID-19 pandemic.
However, lack of awareness and high cost associated with CRRT devices in developing countries are the key factors likely to hamper the growth of the market. In addition, rise in government initiatives for regulatory approval is anticipated to provide lucrative opportunity to key players operating in the market.
The continuous renal replacement therapy market is segmented on the basis of product, modality, age group, and region. Depending on product, the market is classified into dialysates and replacement fluids, disposables, and CRRT systems. Disposables segment is further classified as hemofilters, bloodline sets and tubes, and other disposables. By modality, the market is classified into continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF), continuous venovenous hemodialysis (CVVHD), and slow continuous ultrafiltration (SCUF). According to age group, the market is segmented into pediatric, and adults.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Asia-Pacific accounted for the largest market share in the continuous renal replacement therapy market in 2021 and is expected to retain its dominance throughout the forecast period. This is primarily attributed to increase in number of initiatives along with enhanced investments for the overall R&D of CRRT products. In addition, surge in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture potential growth opportunities boosts the market.
The report provides a comprehensive analysis of the key players that operate in the global continuous renal replacement therapy market. The key companies profiled in the report include Anjue Medical Equipment Co. Ltd., Asahi Kasei Corporation, B. Braun Melsungen AG, Chongqing Shanwaishan Science and Technology Co. Ltd., Cytosorbents, Infomed SA, Medica S.p.A, Medical Components Inc., Medites Pharma spol. s.r.o., Medtronic plc., Nikkiso Co. Ltd., Ningbo Tianyi Medical Devices Co. Ltd., Nipro Corporation, SWS Hemodialysis Care Co. Ltd., Toray Industries Inc., Baxter International Inc., and Fresenius Medical Care AG & Co. KGaA.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the continuous renal replacement therapy market analysis from 2021 to 2031 to identify the prevailing continuous renal replacement therapy market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the continuous renal replacement therapy market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global continuous renal replacement therapy market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product
Dialysates and Replacement Fluids
Disposables
Type
Hemofilters
Bloodline Sets Tubes
Other Disposables
CRRT Systems
By Modality
Slow Continuous Ultrafiltration (SCUF)
Continuous Venovenous Hemofiltration (CVVH)
Continuous Venovenous Hemodiafiltration (CVVHDF)
Continuous Venovenous Haemodialysis (CVVHD)
By Age Group
Adults
Pediatrics
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of LAMEA
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Fresenius Medical Care
Baxter International
Toray Industries Inc.
SWS Hemodialysis Care
Nipro Corporation
Ningbo Tianyi Medical Devices
NIKKISO Co. Ltd
Medtronic plc
Medites Pharma spol. s.r.o
Medical Components Inc.
Medica S.p.A
Infomed SA
Cytosorbents
Chongqing Shanwaishan Science and Technology
B. Braun Melsungen Ag
Asahi Kasei Corporation
Anjue Medical Equipment Co. Ltd
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Dialysates and Replacement Fluids
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Disposables
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.3.4 Disposables Continuous Renal Replacement Therapy Market by Type
- 4.3.4.1 Hemofilters Market size and forecast, by region
- 4.3.4.2 Bloodline Sets & Tubes Market size and forecast, by region
- 4.3.4.3 Other Disposables Market size and forecast, by region
- 4.4 CRRT Systems
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- CHAPTER 5: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Continuous Venovenous Hemofiltration (CVVH)
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Continuous Venovenous Hemodiafiltration (CVVHDF)
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Continuous Venovenous Haemodialysis (CVVHD)
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- 5.5 Slow Continuous Ultrafiltration (SCUF)
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country
- CHAPTER 6: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Adults
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Pediatrics
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- CHAPTER 7: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Product
- 7.2.2.1 North America Disposables Continuous Renal Replacement Therapy Market by Type
- 7.2.3 North America Market size and forecast, by Modality
- 7.2.4 North America Market size and forecast, by Age Group
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Product
- 7.2.5.1.2 Market size and forecast, by Modality
- 7.2.5.1.3 Market size and forecast, by Age Group
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Product
- 7.2.5.2.2 Market size and forecast, by Modality
- 7.2.5.2.3 Market size and forecast, by Age Group
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Product
- 7.2.5.3.2 Market size and forecast, by Modality
- 7.2.5.3.3 Market size and forecast, by Age Group
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Product
- 7.3.2.1 Europe Disposables Continuous Renal Replacement Therapy Market by Type
- 7.3.3 Europe Market size and forecast, by Modality
- 7.3.4 Europe Market size and forecast, by Age Group
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Product
- 7.3.5.1.2 Market size and forecast, by Modality
- 7.3.5.1.3 Market size and forecast, by Age Group
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Product
- 7.3.5.2.2 Market size and forecast, by Modality
- 7.3.5.2.3 Market size and forecast, by Age Group
- 7.3.5.3 UK
- 7.3.5.3.1 Market size and forecast, by Product
- 7.3.5.3.2 Market size and forecast, by Modality
- 7.3.5.3.3 Market size and forecast, by Age Group
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Product
- 7.3.5.4.2 Market size and forecast, by Modality
- 7.3.5.4.3 Market size and forecast, by Age Group
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Product
- 7.3.5.5.2 Market size and forecast, by Modality
- 7.3.5.5.3 Market size and forecast, by Age Group
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Product
- 7.3.5.6.2 Market size and forecast, by Modality
- 7.3.5.6.3 Market size and forecast, by Age Group
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Product
- 7.4.2.1 Asia-Pacific Disposables Continuous Renal Replacement Therapy Market by Type
- 7.4.3 Asia-Pacific Market size and forecast, by Modality
- 7.4.4 Asia-Pacific Market size and forecast, by Age Group
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 China
- 7.4.5.1.1 Market size and forecast, by Product
- 7.4.5.1.2 Market size and forecast, by Modality
- 7.4.5.1.3 Market size and forecast, by Age Group
- 7.4.5.2 Japan
- 7.4.5.2.1 Market size and forecast, by Product
- 7.4.5.2.2 Market size and forecast, by Modality
- 7.4.5.2.3 Market size and forecast, by Age Group
- 7.4.5.3 India
- 7.4.5.3.1 Market size and forecast, by Product
- 7.4.5.3.2 Market size and forecast, by Modality
- 7.4.5.3.3 Market size and forecast, by Age Group
- 7.4.5.4 Australia
- 7.4.5.4.1 Market size and forecast, by Product
- 7.4.5.4.2 Market size and forecast, by Modality
- 7.4.5.4.3 Market size and forecast, by Age Group
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Product
- 7.4.5.5.2 Market size and forecast, by Modality
- 7.4.5.5.3 Market size and forecast, by Age Group
- 7.4.5.6 Rest of LAMEA
- 7.4.5.6.1 Market size and forecast, by Product
- 7.4.5.6.2 Market size and forecast, by Modality
- 7.4.5.6.3 Market size and forecast, by Age Group
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Product
- 7.5.2.1 LAMEA Disposables Continuous Renal Replacement Therapy Market by Type
- 7.5.3 LAMEA Market size and forecast, by Modality
- 7.5.4 LAMEA Market size and forecast, by Age Group
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Product
- 7.5.5.1.2 Market size and forecast, by Modality
- 7.5.5.1.3 Market size and forecast, by Age Group
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Product
- 7.5.5.2.2 Market size and forecast, by Modality
- 7.5.5.2.3 Market size and forecast, by Age Group
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Product
- 7.5.5.3.2 Market size and forecast, by Modality
- 7.5.5.3.3 Market size and forecast, by Age Group
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Product
- 7.5.5.4.2 Market size and forecast, by Modality
- 7.5.5.4.3 Market size and forecast, by Age Group
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 Fresenius Medical Care
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Baxter International
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Toray Industries Inc.
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 SWS Hemodialysis Care
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Nipro Corporation
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Ningbo Tianyi Medical Devices
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 NIKKISO Co. Ltd
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Medtronic plc
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Medites Pharma spol. s.r.o
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Medical Components Inc.
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- 9.11 Medica S.p.A
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
- 9.12 Infomed SA
- 9.12.1 Company overview
- 9.12.2 Company snapshot
- 9.12.3 Operating business segments
- 9.12.4 Product portfolio
- 9.12.5 Business performance
- 9.12.6 Key strategic moves and developments
- 9.13 Cytosorbents
- 9.13.1 Company overview
- 9.13.2 Company snapshot
- 9.13.3 Operating business segments
- 9.13.4 Product portfolio
- 9.13.5 Business performance
- 9.13.6 Key strategic moves and developments
- 9.14 Chongqing Shanwaishan Science and Technology
- 9.14.1 Company overview
- 9.14.2 Company snapshot
- 9.14.3 Operating business segments
- 9.14.4 Product portfolio
- 9.14.5 Business performance
- 9.14.6 Key strategic moves and developments
- 9.15 B. Braun Melsungen Ag
- 9.15.1 Company overview
- 9.15.2 Company snapshot
- 9.15.3 Operating business segments
- 9.15.4 Product portfolio
- 9.15.5 Business performance
- 9.15.6 Key strategic moves and developments
- 9.16 Asahi Kasei Corporation
- 9.16.1 Company overview
- 9.16.2 Company snapshot
- 9.16.3 Operating business segments
- 9.16.4 Product portfolio
- 9.16.5 Business performance
- 9.16.6 Key strategic moves and developments
- 9.17 Anjue Medical Equipment Co. Ltd
- 9.17.1 Company overview
- 9.17.2 Company snapshot
- 9.17.3 Operating business segments
- 9.17.4 Product portfolio
- 9.17.5 Business performance
- 9.17.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 2. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, FOR DIALYSATES AND REPLACEMENT FLUIDS, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR DIALYSATES AND REPLACEMENT FLUIDS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, FOR DISPOSABLES, BY REGION, 2021-2031 ($MILLION)
- TABLE 5. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR DISPOSABLES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 6. GLOBAL DISPOSABLES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 7. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, FOR HEMOFILTERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 8. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, FOR BLOODLINE SETS & TUBES, BY REGION, 2021-2031 ($MILLION)
- TABLE 9. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, FOR OTHER DISPOSABLES, BY REGION, 2021-2031 ($MILLION)
- TABLE 10. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, FOR CRRT SYSTEMS, BY REGION, 2021-2031 ($MILLION)
- TABLE 11. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR CRRT SYSTEMS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 12. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 13. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, FOR CONTINUOUS VENOVENOUS HEMOFILTRATION (CVVH), BY REGION, 2021-2031 ($MILLION)
- TABLE 14. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR CONTINUOUS VENOVENOUS HEMOFILTRATION (CVVH), BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 15. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, FOR CONTINUOUS VENOVENOUS HEMODIAFILTRATION (CVVHDF), BY REGION, 2021-2031 ($MILLION)
- TABLE 16. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR CONTINUOUS VENOVENOUS HEMODIAFILTRATION (CVVHDF), BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 17. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, FOR CONTINUOUS VENOVENOUS HAEMODIALYSIS (CVVHD), BY REGION, 2021-2031 ($MILLION)
- TABLE 18. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR CONTINUOUS VENOVENOUS HAEMODIALYSIS (CVVHD), BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 19. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, FOR SLOW CONTINUOUS ULTRAFILTRATION (SCUF), BY REGION, 2021-2031 ($MILLION)
- TABLE 20. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR SLOW CONTINUOUS ULTRAFILTRATION (SCUF), BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 21. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 22. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, FOR ADULTS, BY REGION, 2021-2031 ($MILLION)
- TABLE 23. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR ADULTS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 24. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, FOR PEDIATRICS, BY REGION, 2021-2031 ($MILLION)
- TABLE 25. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR PEDIATRICS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 26. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 27. NORTH AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 28. NORTH AMERICA DISPOSABLES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 29. NORTH AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 30. NORTH AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 31. NORTH AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 32. U.S. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 33. U.S. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 34. U.S. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 35. CANADA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 36. CANADA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 37. CANADA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 38. MEXICO CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 39. MEXICO CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 40. MEXICO CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 41. EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 42. EUROPE DISPOSABLES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 43. EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 44. EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 45. EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 46. GERMANY CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 47. GERMANY CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 48. GERMANY CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 49. FRANCE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 50. FRANCE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 51. FRANCE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 52. UK CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 53. UK CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 54. UK CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 55. ITALY CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 56. ITALY CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 57. ITALY CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 58. SPAIN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 59. SPAIN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 60. SPAIN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 61. REST OF EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 62. REST OF EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 63. REST OF EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 64. ASIA-PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 65. ASIA-PACIFIC DISPOSABLES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 66. ASIA-PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 67. ASIA-PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 68. ASIA-PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 69. CHINA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 70. CHINA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 71. CHINA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 72. JAPAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 73. JAPAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 74. JAPAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 75. INDIA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 76. INDIA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 77. INDIA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 78. AUSTRALIA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 79. AUSTRALIA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 80. AUSTRALIA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 81. SOUTH KOREA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 82. SOUTH KOREA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 83. SOUTH KOREA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 84. REST OF LAMEA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 85. REST OF LAMEA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 86. REST OF LAMEA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 87. LAMEA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 88. LAMEA DISPOSABLES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 89. LAMEA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 90. LAMEA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 91. LAMEA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 92. BRAZIL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 93. BRAZIL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 94. BRAZIL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 95. SAUDI ARABIA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 96. SAUDI ARABIA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 97. SAUDI ARABIA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 98. SOUTH AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 99. SOUTH AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 100. SOUTH AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 101. REST OF LAMEA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 102. REST OF LAMEA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
- TABLE 103. REST OF LAMEA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 104.FRESENIUS MEDICAL CARE: COMPANY SNAPSHOT
- TABLE 105.FRESENIUS MEDICAL CARE: OPERATING SEGMENTS
- TABLE 106.FRESENIUS MEDICAL CARE: PRODUCT PORTFOLIO
- TABLE 107.FRESENIUS MEDICAL CARE: NET SALES,
- TABLE 108.FRESENIUS MEDICAL CARE: KEY STRATERGIES
- TABLE 109.BAXTER INTERNATIONAL: COMPANY SNAPSHOT
- TABLE 110.BAXTER INTERNATIONAL: OPERATING SEGMENTS
- TABLE 111.BAXTER INTERNATIONAL: PRODUCT PORTFOLIO
- TABLE 112.BAXTER INTERNATIONAL: NET SALES,
- TABLE 113.BAXTER INTERNATIONAL: KEY STRATERGIES
- TABLE 114.TORAY INDUSTRIES INC.: COMPANY SNAPSHOT
- TABLE 115.TORAY INDUSTRIES INC.: OPERATING SEGMENTS
- TABLE 116.TORAY INDUSTRIES INC.: PRODUCT PORTFOLIO
- TABLE 117.TORAY INDUSTRIES INC.: NET SALES,
- TABLE 118.TORAY INDUSTRIES INC.: KEY STRATERGIES
- TABLE 119.SWS HEMODIALYSIS CARE: COMPANY SNAPSHOT
- TABLE 120.SWS HEMODIALYSIS CARE: OPERATING SEGMENTS
- TABLE 121.SWS HEMODIALYSIS CARE: PRODUCT PORTFOLIO
- TABLE 122.SWS HEMODIALYSIS CARE: NET SALES,
- TABLE 123.SWS HEMODIALYSIS CARE: KEY STRATERGIES
- TABLE 124.NIPRO CORPORATION: COMPANY SNAPSHOT
- TABLE 125.NIPRO CORPORATION: OPERATING SEGMENTS
- TABLE 126.NIPRO CORPORATION: PRODUCT PORTFOLIO
- TABLE 127.NIPRO CORPORATION: NET SALES,
- TABLE 128.NIPRO CORPORATION: KEY STRATERGIES
- TABLE 129.NINGBO TIANYI MEDICAL DEVICES: COMPANY SNAPSHOT
- TABLE 130.NINGBO TIANYI MEDICAL DEVICES: OPERATING SEGMENTS
- TABLE 131.NINGBO TIANYI MEDICAL DEVICES: PRODUCT PORTFOLIO
- TABLE 132.NINGBO TIANYI MEDICAL DEVICES: NET SALES,
- TABLE 133.NINGBO TIANYI MEDICAL DEVICES: KEY STRATERGIES
- TABLE 134.NIKKISO CO. LTD: COMPANY SNAPSHOT
- TABLE 135.NIKKISO CO. LTD: OPERATING SEGMENTS
- TABLE 136.NIKKISO CO. LTD: PRODUCT PORTFOLIO
- TABLE 137.NIKKISO CO. LTD: NET SALES,
- TABLE 138.NIKKISO CO. LTD: KEY STRATERGIES
- TABLE 139.MEDTRONIC PLC: COMPANY SNAPSHOT
- TABLE 140.MEDTRONIC PLC: OPERATING SEGMENTS
- TABLE 141.MEDTRONIC PLC: PRODUCT PORTFOLIO
- TABLE 142.MEDTRONIC PLC: NET SALES,
- TABLE 143.MEDTRONIC PLC: KEY STRATERGIES
- TABLE 144.MEDITES PHARMA SPOL. S.R.O: COMPANY SNAPSHOT
- TABLE 145.MEDITES PHARMA SPOL. S.R.O: OPERATING SEGMENTS
- TABLE 146.MEDITES PHARMA SPOL. S.R.O: PRODUCT PORTFOLIO
- TABLE 147.MEDITES PHARMA SPOL. S.R.O: NET SALES,
- TABLE 148.MEDITES PHARMA SPOL. S.R.O: KEY STRATERGIES
- TABLE 149.MEDICAL COMPONENTS INC.: COMPANY SNAPSHOT
- TABLE 150.MEDICAL COMPONENTS INC.: OPERATING SEGMENTS
- TABLE 151.MEDICAL COMPONENTS INC.: PRODUCT PORTFOLIO
- TABLE 152.MEDICAL COMPONENTS INC.: NET SALES,
- TABLE 153.MEDICAL COMPONENTS INC.: KEY STRATERGIES
- TABLE 154.MEDICA S.P.A: COMPANY SNAPSHOT
- TABLE 155.MEDICA S.P.A: OPERATING SEGMENTS
- TABLE 156.MEDICA S.P.A: PRODUCT PORTFOLIO
- TABLE 157.MEDICA S.P.A: NET SALES,
- TABLE 158.MEDICA S.P.A: KEY STRATERGIES
- TABLE 159.INFOMED SA: COMPANY SNAPSHOT
- TABLE 160.INFOMED SA: OPERATING SEGMENTS
- TABLE 161.INFOMED SA: PRODUCT PORTFOLIO
- TABLE 162.INFOMED SA: NET SALES,
- TABLE 163.INFOMED SA: KEY STRATERGIES
- TABLE 164.CYTOSORBENTS: COMPANY SNAPSHOT
- TABLE 165.CYTOSORBENTS: OPERATING SEGMENTS
- TABLE 166.CYTOSORBENTS: PRODUCT PORTFOLIO
- TABLE 167.CYTOSORBENTS: NET SALES,
- TABLE 168.CYTOSORBENTS: KEY STRATERGIES
- TABLE 169.CHONGQING SHANWAISHAN SCIENCE AND TECHNOLOGY: COMPANY SNAPSHOT
- TABLE 170.CHONGQING SHANWAISHAN SCIENCE AND TECHNOLOGY: OPERATING SEGMENTS
- TABLE 171.CHONGQING SHANWAISHAN SCIENCE AND TECHNOLOGY: PRODUCT PORTFOLIO
- TABLE 172.CHONGQING SHANWAISHAN SCIENCE AND TECHNOLOGY: NET SALES,
- TABLE 173.CHONGQING SHANWAISHAN SCIENCE AND TECHNOLOGY: KEY STRATERGIES
- TABLE 174.B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT
- TABLE 175.B. BRAUN MELSUNGEN AG: OPERATING SEGMENTS
- TABLE 176.B. BRAUN MELSUNGEN AG: PRODUCT PORTFOLIO
- TABLE 177.B. BRAUN MELSUNGEN AG: NET SALES,
- TABLE 178.B. BRAUN MELSUNGEN AG: KEY STRATERGIES
- TABLE 179.ASAHI KASEI CORPORATION: COMPANY SNAPSHOT
- TABLE 180.ASAHI KASEI CORPORATION: OPERATING SEGMENTS
- TABLE 181.ASAHI KASEI CORPORATION: PRODUCT PORTFOLIO
- TABLE 182.ASAHI KASEI CORPORATION: NET SALES,
- TABLE 183.ASAHI KASEI CORPORATION: KEY STRATERGIES
- TABLE 184.ANJUE MEDICAL EQUIPMENT CO. LTD: COMPANY SNAPSHOT
- TABLE 185.ANJUE MEDICAL EQUIPMENT CO. LTD: OPERATING SEGMENTS
- TABLE 186.ANJUE MEDICAL EQUIPMENT CO. LTD: PRODUCT PORTFOLIO
- TABLE 187.ANJUE MEDICAL EQUIPMENT CO. LTD: NET SALES,
- TABLE 188.ANJUE MEDICAL EQUIPMENT CO. LTD: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SEGMENTATION
- FIGURE 2.CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031
- FIGURE 3.CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.CONTINUOUS RENAL REPLACEMENT THERAPY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,BY PRODUCT,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF DIALYSATES AND REPLACEMENT FLUIDS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF DISPOSABLES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF CRRT SYSTEMS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031(%)
- FIGURE 16.CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,BY MODALITY,2021(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF CONTINUOUS VENOVENOUS HEMOFILTRATION (CVVH) CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF CONTINUOUS VENOVENOUS HEMODIAFILTRATION (CVVHDF) CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF CONTINUOUS VENOVENOUS HAEMODIALYSIS (CVVHD) CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF SLOW CONTINUOUS ULTRAFILTRATION (SCUF) CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031(%)
- FIGURE 21.CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,BY AGE GROUP,2021(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF ADULTS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF PEDIATRICS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031(%)
- FIGURE 24.CONTINUOUS RENAL REPLACEMENT THERAPY MARKET BY REGION,2021
- FIGURE 25.U.S. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
- FIGURE 26.CANADA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
- FIGURE 27.MEXICO CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
- FIGURE 28.GERMANY CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
- FIGURE 29.FRANCE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
- FIGURE 30.UK CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
- FIGURE 31.ITALY CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
- FIGURE 32.SPAIN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
- FIGURE 33.REST OF EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
- FIGURE 34.CHINA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
- FIGURE 35.JAPAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-20
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook